Literature DB >> 7524604

Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data.

A Zoubek1, C Pfleiderer, M Salzer-Kuntschik, G Amann, R Windhager, F M Fink, E Koscielniak, O Delattre, S Strehl, P F Ambros.   

Abstract

Ewing tumours (ET), including Ewing's sarcoma and peripheral primitive neuroectodermal tumour, are well characterised at the molecular level by a unique chromosomal rearrangement which fuses the EWS gene to one of two closely related ETS proto-oncogenes, FLI-1 or ERG. Expression of the resulting chimaeric transcripts can be readily detected by reversed transcriptase polymerase chain reaction (RT-PCR). This approach led to the identification of a number of different exon combinations at the junction site of coding sequences. The physiological consequences of the observed variability in the hinge region of EWS chimaeric proteins are not known. We have analysed tumour-derived material from 30 ET patients with well-documented clinical course (18 with localised and 12 with metastatic disease at diagnosis) for the presence of EWS/FLI-1 or EWS/ERG RNA. Karyotypes were obtained in 21 out of 27 cases and analysed by routine cytogenetics. A chromosome 22 rearrangement was demonstrated in 18 cases (67%). In contrast, RT-PCR revealed the presence of chimaeric transcripts in 28 tumours (93%), with fusions of EWS exon 7 to FLI-1 exons 6 (19/28), 5 (4/28) and 7 (1/28). In addition, EWS/FLI-1 exon combinations 10/5 and 9/4 were observed in one case each. In the last tumour, the presence of at least four additional splicing variants corresponding to fusion of EWS exon 7 to FLI-1 exons 4, 6, 8 and 9 was demonstrated. Two tumours expressed EWS/ERG fusion transcripts involving EWS exon 7 and ERG exon 6. In this study, EWS/FLI-1 exon combinations 7/6 (type I) predominated over 7/5 (type II) in localised ET (14 versus 1) and were more abundant in tumours affecting the long bones (9 versus 0), whereas in central axis tumours and metastatic disease there was only little difference in the frequency of the two types. So far, no correlations between different chimaeric EWS transcripts and any other clinical parameters have been identified.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524604      PMCID: PMC2033557          DOI: 10.1038/bjc.1994.419

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Mononuclear cell (MNC) concentration from the marrow harvest by automatic system.

Authors:  E Franchini; M Porlezza
Journal:  Haematologica       Date:  1991-03       Impact factor: 9.941

2.  Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial.

Authors:  H Jürgens; U Exner; H Gadner; D Harms; J Michaelis; R Sauer; J Treuner; T Voûte; W Winkelmann; K Winkler
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12).

Authors:  C Turc-Carel; A Aurias; F Mugneret; S Lizard; I Sidaner; C Volk; J P Thiery; S Olschwang; I Philip; M P Berger
Journal:  Cancer Genet Cytogenet       Date:  1988-06

5.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.

Authors:  P H Sorensen; S L Lessnick; D Lopez-Terrada; X F Liu; T J Triche; C T Denny
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

6.  Chromosome translocation in peripheral neuroepithelioma.

Authors:  J Whang-Peng; T J Triche; T Knutsen; J Miser; E C Douglass; M A Israel
Journal:  N Engl J Med       Date:  1984-08-30       Impact factor: 91.245

7.  Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor.

Authors:  H Kovar; M Dworzak; S Strehl; E Schnell; I M Ambros; P F Ambros; H Gadner
Journal:  Oncogene       Date:  1990-07       Impact factor: 9.867

8.  High-dose melphalan, etoposide +/- carboplatin (MEC) combined with 12-gray fractionated total-body irradiation in children with generalized solid tumors.

Authors:  W Emminger; W Emminger-Schmidmeier; R Hawliczek; C Peters; P Höcker; H Gadner
Journal:  Pediatr Hematol Oncol       Date:  1991 Jan-Mar       Impact factor: 1.969

9.  MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration.

Authors:  I M Ambros; P F Ambros; S Strehl; H Kovar; H Gadner; M Salzer-Kuntschik
Journal:  Cancer       Date:  1991-04-01       Impact factor: 6.860

10.  Unexpected heterogeneity in E2A/PBX1 fusion messenger RNA detected by the polymerase chain reaction in pediatric patients with acute lymphoblastic leukemia.

Authors:  S Izraeli; H Kovar; H Gadner; T Lion
Journal:  Blood       Date:  1992-09-15       Impact factor: 22.113

View more
  15 in total

Review 1.  Diagnosis and classification of the small round-cell tumors of childhood.

Authors:  S L Cohn
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

2.  Additional chromosome 1q aberrations and der(16)t(1;16), correlation to the phenotypic expression and clinical behavior of the Ewing family of tumors.

Authors:  B Stark; C Mor; M Jeison; R Gobuzov; I J Cohen; Y Goshen; J Stein; S Fisher; S Ash; I Yaniv; R Zaizov
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Mobilization of tumour cells during biopsy in an infant with Ewing sarcoma.

Authors:  A Zoubek; H Kovar; M Kronberger; G Amann; R Windhager; B Gruber; H Gadner
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

4.  Molecular diagnosis in Ewing family tumors: the Rizzoli experience--222 consecutive cases in four years.

Authors:  Gabriella Gamberi; Stefania Cocchi; Stefania Benini; Giovanna Magagnoli; Luca Morandi; Jennifer Kreshak; Marco Gambarotti; Piero Picci; Licciana Zanella; Marco Alberghini
Journal:  J Mol Diagn       Date:  2011-03-31       Impact factor: 5.568

Review 5.  Ewing tumour: incidence, prognosis and treatment options.

Authors:  M Paulussen; B Fröhlich; H Jürgens
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

6.  Multiple splice variants of EWSR1-ETS fusion transcripts co-existing in the Ewing sarcoma family of tumors.

Authors:  Barbara Patócs; Krisztina Németh; Miklós Garami; Gabriella Arató; Ilona Kovalszky; Miklós Szendrői; György Fekete
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

7.  Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.

Authors:  Patrick J Grohar; Suntae Kim; Guillermo O Rangel Rivera; Nirmalya Sen; Sara Haddock; Matt L Harlow; Nichole K Maloney; Jack Zhu; Maura O'Neill; Tamara L Jones; Konrad Huppi; Magdalena Grandin; Kristen Gehlhaus; Carleen A Klumpp-Thomas; Eugen Buehler; Lee J Helman; Scott E Martin; Natasha J Caplen
Journal:  Cell Rep       Date:  2016-01-14       Impact factor: 9.423

8.  Intraoperative dissemination of tumour cells in patients with Ewing tumours detected by RT-PCR.

Authors:  J G Grohs; A Zoubek; D Jugovic; H Kovar; R Windhager
Journal:  Int Orthop       Date:  2004-03-16       Impact factor: 3.075

9.  Distinct genomic aberrations associated with ERG rearranged prostate cancer.

Authors:  Francesca Demichelis; Sunita R Setlur; Rameen Beroukhim; Sven Perner; Jan O Korbel; Christopher J Lafargue; Dorothee Pflueger; Cara Pina; Matthias D Hofer; Andrea Sboner; Maria A Svensson; David S Rickman; Alex Urban; Michael Snyder; Matthew Meyerson; Charles Lee; Mark B Gerstein; Rainer Kuefer; Mark A Rubin
Journal:  Genes Chromosomes Cancer       Date:  2009-04       Impact factor: 5.006

10.  Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors.

Authors:  Nathaniel D Anderson; Richard de Borja; Matthew D Young; Fabio Fuligni; Andrej Rosic; Nicola D Roberts; Simon Hajjar; Mehdi Layeghifard; Ana Novokmet; Paul E Kowalski; Matthew Anaka; Scott Davidson; Mehdi Zarrei; Badr Id Said; L Christine Schreiner; Remi Marchand; Joseph Sitter; Nalan Gokgoz; Ledia Brunga; Garrett T Graham; Anthony Fullam; Nischalan Pillay; Jeffrey A Toretsky; Akihiko Yoshida; Tatsuhiro Shibata; Markus Metzler; Gino R Somers; Stephen W Scherer; Adrienne M Flanagan; Peter J Campbell; Joshua D Schiffman; Mary Shago; Ludmil B Alexandrov; Jay S Wunder; Irene L Andrulis; David Malkin; Sam Behjati; Adam Shlien
Journal:  Science       Date:  2018-08-31       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.